[go: up one dir, main page]

SI1888643T1 - Protitelesa proti gm-csf in uporabe zanje - Google Patents

Protitelesa proti gm-csf in uporabe zanje

Info

Publication number
SI1888643T1
SI1888643T1 SI200631880T SI200631880T SI1888643T1 SI 1888643 T1 SI1888643 T1 SI 1888643T1 SI 200631880 T SI200631880 T SI 200631880T SI 200631880 T SI200631880 T SI 200631880T SI 1888643 T1 SI1888643 T1 SI 1888643T1
Authority
SI
Slovenia
Prior art keywords
uses therefor
csf antibodies
csf
antibodies
therefor
Prior art date
Application number
SI200631880T
Other languages
English (en)
Inventor
Stefan Steidl
Elisabeth Thomassen-Wolf
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of SI1888643T1 publication Critical patent/SI1888643T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI200631880T 2005-05-18 2006-05-17 Protitelesa proti gm-csf in uporabe zanje SI1888643T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68200905P 2005-05-18 2005-05-18
PCT/EP2006/004696 WO2006122797A2 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor
EP06742970.4A EP1888643B1 (en) 2005-05-18 2006-05-17 Anti-gm-csf antibodies and uses therefor

Publications (1)

Publication Number Publication Date
SI1888643T1 true SI1888643T1 (sl) 2015-03-31

Family

ID=37114333

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200631880T SI1888643T1 (sl) 2005-05-18 2006-05-17 Protitelesa proti gm-csf in uporabe zanje
SI200632423T SI3620171T1 (sl) 2005-05-18 2006-05-17 Protitelesa proti GM-CSF in uporabe zanje

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200632423T SI3620171T1 (sl) 2005-05-18 2006-05-17 Protitelesa proti GM-CSF in uporabe zanje

Country Status (26)

Country Link
US (5) US7867495B2 (sl)
EP (4) EP1888643B1 (sl)
JP (2) JP5295759B2 (sl)
KR (1) KR101308087B1 (sl)
CN (2) CN103087190B (sl)
AR (1) AR053608A1 (sl)
AU (1) AU2006249062B2 (sl)
BR (1) BRPI0610796B8 (sl)
CA (1) CA2608498C (sl)
CY (2) CY1115920T1 (sl)
DK (2) DK3620171T3 (sl)
ES (2) ES2918209T3 (sl)
HR (2) HRP20150023T1 (sl)
HU (1) HUE058876T2 (sl)
IL (1) IL187375A (sl)
LT (1) LT3620171T (sl)
ME (1) ME02059B (sl)
NO (1) NO344992B1 (sl)
NZ (1) NZ564027A (sl)
PL (2) PL3620171T3 (sl)
PT (2) PT3620171T (sl)
RS (2) RS53743B1 (sl)
RU (1) RU2447085C2 (sl)
SI (2) SI1888643T1 (sl)
TW (1) TWI477512B (sl)
WO (1) WO2006122797A2 (sl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219616A (zh) * 2016-09-19 2019-01-15 天境生物 Gm-csf抗体及其用途

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874819B1 (en) 2005-04-18 2015-05-27 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
HUE058876T2 (hu) * 2005-05-18 2022-09-28 Morphosys Ag Anti-GM-CSF antitestek és felhasználásuk
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
ES2609088T3 (es) * 2006-02-08 2017-04-18 Morphotek, Inc. Péptidos GM-CSF antigénicos y anticuerpos anti-GM-CSF
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
EP2160407A4 (en) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd NEUTRALIZING ANTIBODIES
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20100297135A1 (en) * 2007-11-12 2010-11-25 Crc For Asthma And Airways Ltd. Epitope for neutralizing antibodies
PT2215119E (pt) 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
PL2215121T3 (pl) 2007-11-26 2016-07-29 Bayer Ip Gmbh Przeciwciała przeciwko mezotelinie i ich zastosowania
EP2088432A1 (en) * 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
AU2009243184B2 (en) * 2008-04-28 2015-06-04 Humanigen, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
KR20110044991A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＮＦ-α 길항제 다-표적 결합 단백질
EP3056217B1 (en) * 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
KR101761324B1 (ko) * 2008-12-22 2017-07-25 더 유니버시티 오브 멜버른 통증 치료
CA2759506A1 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
JP2012530047A (ja) * 2009-05-05 2012-11-29 モルフォシス・アー・ゲー 多発性硬化症のための治療
KR20140061379A (ko) * 2011-07-06 2014-05-21 모르포시스 아게 항­ｃｄ20 및 항­ｇｍ­ｃｓｆ 항체의 치료 조합물 및 이의 용도
US9901079B2 (en) * 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
CA2871417C (en) 2012-04-23 2021-08-31 Genefrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
ES2734130T3 (es) 2012-08-17 2019-12-04 Morphosys Ag Anticuerpos específicos de complejos y fragmentos de anticuerpo y su uso
KR20150056846A (ko) * 2012-09-20 2015-05-27 모르포시스 아게 류마티스 관절염에 대한 치료
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
AU2013342779B2 (en) 2012-11-09 2019-09-26 Genefrontier Corporation Anti-ADAM28 antibody for treating cancer
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
AU2014314053C1 (en) 2013-08-30 2023-11-02 Takeda Pharmaceutical Company Limited Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
JP6202339B2 (ja) 2013-12-19 2017-09-27 国立研究開発法人国立精神・神経医療研究センター ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤
CN106659785B (zh) 2014-05-07 2021-04-30 武田有限公司 包含gm-csf中和化合物的液体制剂
JP6490419B2 (ja) * 2014-12-24 2019-03-27 学校法人関西医科大学 制御性ｔ細胞分化誘導剤
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
WO2016143702A1 (ja) 2015-03-06 2016-09-15 ジーンフロンティア株式会社 抗ヒト膜型ａｄａｍ２８抗体
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11673962B2 (en) 2017-10-02 2023-06-13 Humanigen, Inc. Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2020078270A1 (en) 2018-10-15 2020-04-23 Elixiron Immunotherapeutics (hong Kong) Limited Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
JP7495403B2 (ja) 2018-11-09 2024-06-04 キニクサ ファーマシューティカルズ， リミテッド 巨細胞性動脈炎の治療
CN113677356A (zh) * 2019-01-07 2021-11-19 湖南思为康医药有限公司 用于降低毒性的共表达嵌合抗原受体和il-6拮抗剂的修饰免疫细胞及其在过继细胞疗法中的用途
US20220331425A1 (en) 2019-06-03 2022-10-20 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
NL2036015B1 (en) 2023-10-12 2025-04-30 Micronit Holding B V A method of manufacturing a nozzle assembly, comprising weakening a wafer at at least two focal zones in the depth direction by focusing a laser beam
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
EP1144607B1 (en) 1999-07-20 2008-12-17 MorphoSys AG Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
ES2365606T3 (es) 2002-02-13 2011-10-07 Ludwig Institute For Cancer Research Ltd. Anticuerpos contra gm-csf quiméricos.
US7754450B2 (en) 2002-11-15 2010-07-13 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
HUE058876T2 (hu) * 2005-05-18 2022-09-28 Morphosys Ag Anti-GM-CSF antitestek és felhasználásuk

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219616A (zh) * 2016-09-19 2019-01-15 天境生物 Gm-csf抗体及其用途

Also Published As

Publication number Publication date
JP5295759B2 (ja) 2013-09-18
BRPI0610796A2 (pt) 2010-11-09
EP3620171B1 (en) 2022-04-20
US20200024340A1 (en) 2020-01-23
LT3620171T (lt) 2022-06-10
US20170218061A1 (en) 2017-08-03
AU2006249062A1 (en) 2006-11-23
CN103087190B (zh) 2016-08-03
PT3620171T (pt) 2022-06-30
PL3620171T3 (pl) 2022-08-08
US10377820B2 (en) 2019-08-13
US7867495B2 (en) 2011-01-11
ES2918209T3 (es) 2022-07-14
IL187375A (en) 2012-06-28
US20110045000A1 (en) 2011-02-24
US20210347879A1 (en) 2021-11-11
ME02059B (me) 2015-05-20
EP2468773A3 (en) 2012-09-19
RS53743B1 (sr) 2015-06-30
SI3620171T1 (sl) 2022-09-30
ES2527428T3 (es) 2015-01-23
RU2007147870A (ru) 2009-06-27
PT1888643E (pt) 2015-01-14
CY1125427T1 (el) 2025-05-09
DK1888643T3 (en) 2015-01-05
CY1115920T1 (el) 2017-01-25
HK1114620A1 (en) 2008-11-07
DK3620171T3 (da) 2022-06-07
US9751939B2 (en) 2017-09-05
US20090053213A1 (en) 2009-02-26
US11028165B2 (en) 2021-06-08
WO2006122797A2 (en) 2006-11-23
RU2447085C2 (ru) 2012-04-10
CN101218255B (zh) 2013-01-09
NO20076437L (no) 2007-12-13
KR101308087B1 (ko) 2013-10-16
AR053608A1 (es) 2007-05-09
HRP20150023T1 (hr) 2015-02-27
EP1888643A2 (en) 2008-02-20
KR20080015008A (ko) 2008-02-15
TWI477512B (zh) 2015-03-21
JP2013116912A (ja) 2013-06-13
BRPI0610796B1 (pt) 2020-01-21
JP2008545632A (ja) 2008-12-18
WO2006122797A3 (en) 2007-02-15
EP2468773A2 (en) 2012-06-27
BRPI0610796B8 (pt) 2021-05-25
NO344992B1 (no) 2020-08-17
EP3620171A1 (en) 2020-03-11
WO2006122797B1 (en) 2007-04-19
AU2006249062B2 (en) 2012-12-20
HRP20220755T3 (hr) 2022-09-02
IL187375A0 (en) 2008-02-09
CN103087190A (zh) 2013-05-08
RS63382B1 (sr) 2022-08-31
CN101218255A (zh) 2008-07-09
EP3150221A1 (en) 2017-04-05
CA2608498A1 (en) 2006-11-23
TW200716674A (en) 2007-05-01
HUE058876T2 (hu) 2022-09-28
JP5769744B2 (ja) 2015-08-26
EP1888643B1 (en) 2014-10-29
PL1888643T3 (pl) 2015-04-30
NZ564027A (en) 2011-06-30
CA2608498C (en) 2017-04-04

Similar Documents

Publication Publication Date Title
IL187375A0 (en) Anti-gm-csf antibodies and uses therefor
IL272883A (en) Monoclonal antibodies and their uses
IL222922A (en) Antibodies against neurophilin-1 and their use
IL184024A0 (en) Irta-5 antibodies and their uses
IL184659A0 (en) Antibody variants and uses thereof
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
IL182554A0 (en) Anti-addl antibodies and uses thereof
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
IL191820A0 (en) Anti-ox40l antibodies and methods using same
IL235620A0 (en) sp35 antibodies and their uses
IL196397A0 (en) Prlr-specific antibody and uses thereof
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
IL192266A0 (en) Anti-ilt7 antibody
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
IL185366A0 (en) Antibody
IL178277A0 (en) Irta-5 antibodies and their uses
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
ZA200702281B (en) IRTA-4 antibodies and their uses
ZA200705716B (en) IRTA-2 antibodies and their uses
GB0507219D0 (en) Antibody and uses thereof
GB0507272D0 (en) Antibody and uses thereof
GB0500400D0 (en) Antibody